Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

In this study, researchers developed and tested an Italian version of the Skindex-16AA to assess Health-Related Quality of Life in patients with moderate-to-severe Alopecia Areata, emphasizing the importance of patient perception in evaluating their mental health and quality of life.

Machine learning can use blood tests to help predict moderate-to-severe alopecia areata.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This study suggests that potent topical corticosteroid occlusion may be a safe and effective treatment option for pediatric patients with severe alopecia areata, although further research is needed on its long-term safety and recurrence.

This study used advanced single-cell RNA and chromatin sequencing to investigate differences in peripheral blood cells between mild and severe alopecia areata patients, uncovering shared transcription factor motifs that may explain disease severity and open avenues for future research on therapeutic targets.

In this study, researchers used high-resolution MRI to distinguish anatomical differences in the scalp and hair follicles between tertiary androgenetic alopecia and severe alopecia areata, identifying subcutaneous tissue layer thickness as a key discriminative factor with high diagnostic value.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This study identified specific miRNAs that are potentially linked to severe active alopecia areata, suggesting they could be targets for future treatment development.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

This review discusses vaccine safety concerns for individuals with autoimmune and inflammatory conditions, noting vaccine hesitancy due to observed exacerbations post-vaccination and a lack of comprehensive trial data.

This study found that ritlecitinib 50 mg is cost-effective compared to no treatment for patients in Japan with alopecia areata and significant scalp hair loss, demonstrating an incremental cost-effectiveness ratio below the country's cost-effectiveness threshold.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.

This study found that overexpression of miR-1246 in peripheral CD4+ T cells can reduce markers associated with inflammation and T cell activation in severe active alopecia areata, suggesting potential therapeutic benefits.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This study found that alopecia areata patients in Central Europe with comorbid chronic inflammatory disorders, especially atopic dermatitis, bronchial asthma, or Hashimoto's thyroiditis, had an increased likelihood of experiencing early-onset, severe, or prolonged disease compared to those without such comorbidities.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

In this study, intralesional triamcinolone acetonide was found to be more effective than platelet rich plasma and placebo for moderate to severe alopecia areata, but had a higher relapse rate.

People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.

In this study, nail changes, particularly pitting, were associated with moderate to severe cases of alopecia areata and a positive family history, highlighting potential genetic factors in the condition.

This report describes two young women with severe psoriasis and alopecia universalis, highlighting the possible but unstudied association between alopecia areata and metabolic syndrome.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

This source evaluates the clinical effectiveness of 308 nm monochromatic excimer phototherapy in treating moderate-to-severe alopecia areata, noting that both laser and lamp methods show promise without significant risks.